-

Tempus Introduces Workspaces into its Lens Data Analytics Platform

Lens is trusted by nearly 100 institutions to uncover novel insights

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, is broadly introducing its new Workspaces feature in the Lens platform. Workspaces is a private, coding-based cloud environment designed to unblock research and accelerate innovation. This new interface provides researchers a frictionless workflow for surfacing critical insights to power scientific discovery and development.

Lens is already trusted by nearly 100 institutions, including healthcare systems and biopharma companies, to power research that improves patient outcomes. Lens provides access to more than 200 petabytes of de-identified multimodal datasets, as well as a suite of tools that enable rapid time-to-insight, flexible analyses, and collaboration. In addition to Workspaces, other new features include the integration of Tempus One, an AI assistant that makes the vast amounts of data more accessible, and Cohort Builder, which helps define cohorts of interest by leveraging the platform’s rich molecular and clinical filters, including, cancer diagnosis, HLA genotype, comorbidities and more.

The new Workspaces feature enables users to easily leverage virtual machines designed to support a variety of research goals, query and analyze data directly in popular coding languages like python and R, and run tailored analyses using Tempus’s library of analytic templates. The flexibility it provides is the perfect complement to Lens’ other pre-built visualization tools that allow for faster time-to-insight and understand demographics, distribution, and prevalence across cohorts of interest.

“We’ve heavily invested in designing Lens to be the most seamless and fastest way to translate multimodal data into pivotal insights, and we’re proud that many institutions already rely on it for their research needs,” said Ryan Fukushima, Chief Operating Officer at Tempus. “Workspaces is flexible and fast, offering multiple virtual machine types to support diverse analytical needs and rapidly surface critical insights that can shape the future of oncology care."

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Tempus


Release Versions

Contacts

Social Media Profiles
More News From Tempus

Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune Profile Score (IPS), more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) than conventional biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), and PD-L1. IPS is a multimodal biomarker that combin...

Tempus Announces the Launch of Paige Predict

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of Paige Predict, a suite of cutting-edge digital pathology applications that analyze hematoxylin and eosin (H&E) whole slide images to help inform testing decisions. The AI-powered solution is designed to predict the likely presence or absence of clinically actionable and relevant biomarkers directly from a single H&E slide,...

Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation’s premier academic medical centers, today announced a multi-year strategic collaboration aimed at transforming cancer care through advanced molecular profiling and data-driven insights. The collaboration will support NYU Langone Health’s Center for Molecular Oncology at the Laura and Isaac Perlmutter Cancer Center, a comprehensive, pan-cancer initiative to more...
Back to Newsroom